Using T cells to treat pancreatic cancer
Adoptive T Cell Therapy for Pancreatic Cancer
This study is testing a new way to treat pancreatic cancer by using special immune cells to better fight the tumors, and it's designed for patients looking for more effective options in a disease that hasn't seen much improvement in survival rates.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10686371 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for pancreatic cancer by using adoptive T cell therapy. It aims to enhance the immune response against pancreatic tumors by transferring T cells that specifically target cancer-associated antigens. The study addresses key challenges in this approach, such as identifying effective immunogenic targets and rapidly deploying these targeted T cells. By combining this therapy with immune checkpoint inhibitors, the research seeks to improve patient outcomes in a disease that has seen little progress in survival rates over the past 40 years.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who have limited treatment options.
Not a fit: Patients with early-stage pancreatic cancer or those who do not have specific tumor-associated antigens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for pancreatic cancer patients, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in using adoptive T cell therapy for other cancers, but this approach for pancreatic cancer is still being explored and is considered novel.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Yee, Cassian — University of Tx Md Anderson Can Ctr
- Study coordinator: Yee, Cassian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.